Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment

GlaxoSmithKline4,376 enrolled

Overview

Quality of Life (QoL) in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Cross-sectional quality of life survey using self-administered OPSAT-QTM questionnaire in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Study Type

OBSERVATIONAL

Enrollment

4,376

Conditions

Osteoporosis, Postmenopausal

Interventions

OPSAT-QOTHER

A linguistically validated Korean version of OPSAT-Q

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Who have been diagnosed with postmenopausal osteoporosis by physician Who have received any oral bisphosphonates (weekly or monthly) at least for 2 months to provide answer of OPSAT-QTM questionnaire Who provide informed consent for study participation Exclusion Criteria: * Do not understand the contents of the questionnaire

Locations (1)

GSK Investigational Site

Seoul, South Korea

Outcomes

Primary Outcomes

Mean of composite satisfaction score (CSS) of OPSAT-QTM

Time frame: 0day

Secondary Outcomes

Mean of subscale satisfaction scores of OPSAT-QTM

Time frame: oday

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.